Recombinant follicle-stimulating hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome.
OBJECTIVE
To compare the low-dose recombinant FSH and hMG protocols in treatment of patients with history of severe ovarian hyperstimulation syndrome (OHSS).


METHODS
A prospective study on 22 patients with history of severe OHSS. Group A (n = 14) was treated with low-dose recombinant FSH 40 cycles and group B (n = 8) was treated with low-dose hMG in 26 cycles.


METHODS
The Egyptian IVF-ET Center, Cairo, Egypt.


METHODS
Twenty-two patients with a history of severe OHSS.


METHODS
Ovulation induction.


METHODS
Estradiol, number of follicles, number of hMG ampules, pregnancy rate (PR), and the development of OHSS.


RESULTS
The cancellation rate, mean E2 level on day of hCG, mean number of days of stimulation, and the mean number of ampules per cycle were 10%, 523 +/- 166 pg/mL (conversion factor to SI unit, 3.671), 17.8 +/- 5.4, and 19 +/- 6.5 in group A and 19.2%, 554 +/- 152 pg/mL, 14.6 +/- 2.5, and 16.1 +/- 3.6 in group B, respectively. Treatment resulted in eight pregnancies (20% per cycle) and two abortions (25%) in group A. In group B, four pregnancies resulted (15.4% per cycle) and two patients aborted (50%). No cases of OHSS developed in both groups. There were no significant differences in all parameters between the two groups.


CONCLUSIONS
Recombinant FSH low-dose protocol proved to be as effective as low-dose hMG in producing reasonable ovulation and PRS in polycystic ovary syndrome patients with a history of severe OHSS and the protocol was safe concerning the risk of development of OHSS.
Egyptian IVF-ET Center, Cairo, Egypt.
M A
MA
Aboulghar
R T
RT
Mansour
G I
GI
Serour
Y M
YM
Amin
M A
MA
Sattar
E
E
elAttar
D000022:Abortion, Spontaneous; D004534:Egypt; D004624:Embryo Transfer; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008596:Menotropins / Q000627:therapeutic use; D016471:Ovarian Hyperstimulation Syndrome / Q000517:prevention & control*; D011247:Pregnancy; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors
D011994:Recombinant Proteins; D004958:Estradiol; D008596:Menotropins; D005640:Follicle Stimulating Hormone